HIV Infection Negatively Affects Bone Acquisition

This article originally appeared here.
Share this content:
HIV Infection Negatively Affects Bone Acquisition
HIV Infection Negatively Affects Bone Acquisition

WEDNESDAY, June 15, 2016 (HealthDay News) -- HIV infection with T cell activation is associated with lower bone mineral density (BMD) and stiffness, according to a study published online June 10 in the Journal of Bone and Mineral Research.

John S. Manavalan, M.D., from the Columbia University Medical Center in New York City, and colleagues used dual X-ray absorptiometry (DXA) and high-resolution peripheral quantitative computed tomography (HRpQCT) to characterize BMD and microarchitecture in 38 HIV-infected men on antiretroviral therapy (18 perinatally-infected and 20 adolescence-infected) and 20 uninfected men aged 20 to 25 years.

The researchers found that, compared with uninfected men, HIV-infected men had lower DXA derived areal BMD Z-scores and HRpQCT derived volumetric BMD measures. HIV-infected men had higher proportions of activated and senescent CD4+ and CD8+ T cells compared with uninfected men. HIV-infected men had a lower percentage of circulating osteogenic precursor (COP) cells than uninfected men (0.19 ± 0.02 versus 0.43 ± 0.06 percent; P < 0.001); the proportion was also lower in perinatally- versus adolescence-infected men (0.15 ± 0.02 versus 0.22 ± 0.03 percent; P < 0.04). Higher bone stiffness was seen with a higher proportion of COP cells, while a higher proportion of activated CD4+ T cells was associated with decreased BMD and stiffness and a lower proportion of COP cells.

"T cell activation with HIV-infection was associated with decreased numbers of osteogenic precursors as well as lower peak bone mass and bone strength," the authors write.

One author disclosed financial ties to Gilead and AbbVie.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »